Federica Veronese
Novara, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?
Journal: Italian journal of dermatology and venereology
Published: December 11, 2025
Therapy-Dependent Modulation of Staphylococcus aureus Colonization in Atopic Dermatitis: Insights from Anti-IL-4/IL-13 and JAK Inhibition.
Journal: Journal of the American Academy of Dermatology
Published: December 09, 2025
Therapy-dependent modulation of Staphylococcus aureus colonization in atopic dermatitis: Insights from anti-IL-4/IL-13 and JAK inhibition.
Journal: Journal of the American Academy of Dermatology
Published: December 09, 2025
From north to south: exploring Italian sun-exposure habits through the "Save your skin" campaign.
Journal: European journal of dermatology : EJD
Published: November 24, 2025
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.
Journal: Clinical and experimental dermatology
Published: October 21, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: August 12, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study.
Journal: Antibodies (Basel, Switzerland)
Published: July 24, 2025
A single-center prospective observational study evaluating the efficacy and safety of tirbanibulin 1% in actinic keratoses in immunosuppressed patients: the ESTIMATE study.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: June 21, 2025
Skin microbiota in atopic dermatitis: victim or executioner?
Journal: Clinical microbiology reviews
Published: June 03, 2025
Last Updated: 09/26/2026